Here are relevant reports on : parkinsons-disease-market
-
Pharmacogenomics Market by Product & Service (Kits & Reagents), Technology (Sequencing, PCR, Microarray), Application (Drug Discovery, Clinical Research, Personalized Medicine), Disease Area (Cancer, Neurological, Cardiovascular) - Global Forecast to 2028
The global pharmacogenomics market, valued at US$3.3 billion in 2022, stood at US$3.5 billion in 2023 and is projected to advance at a resilient CAGR of 10.6% from 2023 to 2028, culminating in a forecasted valuation of US$5.8 billion by the end of the period. The increasing focus on the translational approach to optimize drug development processes, increasing collaborations and partnerships between key players and research institutes, and rising incidence of cancer are the major driving factors of the pharmacogenomics market.
- Published: February 2024
- Price: $ 4950
- TOC Available:
-
DNA Diagnostics Market by Product (Instruments, Reagents & Kits, Services & Software), Technology (PCR, Mass Spectroscopy, Microarrays), Application (Infectious Disease (Hepatitis, HIV, HPV), Oncology), Specimen (Blood, Urine) - Global Forecast to 2029
The global DNA diagnostics market, valued at US$12.3 billion in 2023, stood at US$13.3 billion in 2024 and is projected to advance at a resilient CAGR of 9.7% from 2024 to 2029, culminating in a forecasted valuation of US$21.2 billion by the end of the period. Growth in the market is primarily driven by the technological improvements in the DNA diagnostics industry and the growing need for personalized treatment and early disease diagnosis in developing nations. Also, the increased investments by healthcare-based companies are majorly contributing to growth of the market.
- Published: July 2024
- Price: $ 4950
- TOC Available:
-
Vaccine Adjuvants Market by Product (Emulsions, Pathogen, Saponin, Particulate), ROA (Subcutaneous, Intramuscular), Disease Type (Infectious, Cancer), Vaccine (Human, Veterinary (Companion, Livestock)), Type (Organic, Inorganic) - Global Forecast to 2029
The global vaccine adjuvants market, valued at US$0.66 billion in 2023, stood at US$0.70 billion in 2024 and is projected to advance at a resilient CAGR of 6.5% from 2024 to 2029, culminating in a forecasted valuation of US$0.96 billion by the end of the period. Growing awareness about livestock health, increasing the adoption of companion animals and developing of therapeutic vaccines for cancer, allergies, and autoimmune disorders are creating lucrative growth opportunities
- Published: December 2024
- Price: $ 4950
- TOC Available:
-
Antibody Drug Conjugates (ADC) Market by Product (Kadcyla, Enhertu, Padcev, Polivy), Linker Type (Cleavable, Non-Cleavable), Payload Type (Calicheamicin, MMAE), Target (HER2, CD30, CD22), Disease, Region - Global Forecast to 2028
The global antibody drug conjugates market, valued at US$7.6 billion in 2022, stood at US$9.7 billion in 2023 and is projected to advance at a resilient CAGR of 15.2% from 2025 to 2028, culminating in a forecasted valuation of US$19.8 billion by the end of the period. Growth in the market can be attributed to various factors such as including the growing prevalence of cancer, and increasing R&D activities for the development of novel ADCs by key market players.
- Published: October 2023
- Price: $ 4950
- TOC Available:
-
Asia Pacific Vaccines Market by Technology (Conjugate, Recombinant, Inactivated, Live Attenuated, Viral Vector), Type (Monovalent, Multivalent), Disease (Pneumococcal, Flu, Hepatitis, MMR), Route of Administration (IM, SC, Oral) - Forecast to 2030
The Asia Pacific Vaccines market, valued at USD 9.46 billion in 2024, stood at USD 9.89 billion in 2025 and is projected to advance at a resilient CAGR of 9.0% from 2025 to 2030, culminating in a forecasted valuation of USD14.57 billion by the end of the period. The market is expanding quickly, driven by a rise in vaccine development and commercialization, heightened infectious disease rates, and the extensive use of preventive vaccines.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
Anatomic Pathology Market by Product [Consumables (Histopathology, Cytopathology), Instruments, Software], Process, Disease (Breast, GI, Prostate), End User (Hospitals, Research Labs), Services, Model (In House, Outsourced) – Global Forecast to 2031
The global anatomic pathology market is projected to reach USD 14.5 billion by 2031, growing at a CAGR of 10.2% during the forecast period (2026–2031). The report covers key segments, regional analysis, and competitive landscape across the market ecosystem.
- Published: August 2026
- Price: $ 4950
- TOC Available:
-
C – Reactive Protein Testing Market by Assay Type (ELISA, Turbidimetric, Immunoturbidimetric), Application (Cardiovascular, Inflammatory Disease, Rheumatoid Arthritis, Cancer), End User (Hospitals, Clinics, Diagnostics Labs) - Global Forecast to 2023
The Global C-Reactive Protein Testing market is expected to reach USD 1.75 billion by 2023 from USD 1.62 billion in 2018, growing at a CAGR of 1.5 % from 2018 to 2023. Growing occurrences of Non Communicable Diseases (NCDs) such as Cardiovascular Diseases, Diabetes and other inflammatory diseases are the major drivers for this market. Point of Care technology for CRP testing is also being used for diagnostic purposes.
- Published: September 2026
- Price: $ 4950
- TOC Available:
-
Cattle & Porcine/Swine Reproductive Diseases Market by Product (Diagnostics (ELISA, PCR, Rapid Antigen Testing), Pharmaceuticals (Vaccines), Supplements, Animal Type, Disease (BVD, PRRS, Leptospirosis, Brucellosis), End User - Global Forecast to 2029
The global cattle & porcine/swine reproductive diseases market, valued at US$726.9 million in 2023, stood at US$758.2 million in 2024 and is projected to advance at a resilient CAGR of 5.2% from 2024 to 2029, culminating in a forecasted valuation of US$975.8 million by the end of the period. Increasing investments, funding, and grants from various governments and organizations to improve animal health, along with a growing number of veterinarians in developing nations, are enhancing the treatment of diseases.
- Published: October 2024
- Price: $ 4950
- TOC Available:
-
Skin Cancer Drugs Market by Type (Chemotherapy, Immunotherapy), Disease Indication (Melanoma, Basal and Squamous), Distribution Channel – Global Forecast to 2027
The global skin cancer drugs market is projected to reach USD ~6 billion by 2027 from USD 4 billion in 2022, at a CAGR of 9 % during the forecast period
- Published: September 2026
- Price: $ 4950
- TOC Available:
-
Human Microbiome Drugs Market by Type (Live Biotherapeutic Products, Fecal Microbiota-derived Therapeutics), Disease (Gastrointestinal, Infectious), End User (Hospitals, Clinics, Long-term Care) - Global Forecast to 2031
The human microbiome drugs market, valued at US$0.09 billion in 2024, stood at US$0.35 billion in 2025 and is projected to advance at a resilient CAGR of 35.2% from 2025 to 2031, culminating in a forecasted valuation of US$2.13 billion by the end of the period. The human microbiome drugs market is growing, driven by the increasing clinical success of live biotherapeutic products, rising prevalence of chronic and recurrent diseases, and expanding therapeutic applications beyond gastrointestinal disorders into metabolic, immune, and neurological conditions.
- Published: August 2026
- Price: $ 4950
- TOC Available:
Records 31 to 40 of 50
